Pathology

GE HealthCare Accelerates AI Innovation with Healthcare-Specific Foundation Models Powered by NVIDIA

Retrieved on: 
Monday, March 18, 2024
Other Health, Software, General Health, Radiology, Data Management, Apps, Applications, Medical Devices, Technology, Artificial Intelligence, Health Technology, Biotechnology, Health, Medicine, Distillation, Biomarker, Research, Health care, Sale, Artificial intelligence, Business development, AI, GE HealthCare, Heart, Pathology, NVIDIA

“GE HealthCare is committed to investing in innovative technologies that help tackle some of the industry’s biggest challenges.

Key Points: 
  • “GE HealthCare is committed to investing in innovative technologies that help tackle some of the industry’s biggest challenges.
  • This is particularly significant in the healthcare domain, for which data is especially time-consuming and costly to obtain,” said Parminder Bhatia, Chief AI Officer, GE HealthCare.
  • In healthcare, leveraging AI to enhance patient care, streamline operational efficiencies, and make informed decisions has become increasingly important.
  • Foundation models have risen to prominence due to their ability to operate as human-in-the-loop AI systems, garnering significant attention.

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

Retrieved on: 
Monday, March 18, 2024
Mental Health, Managed Care, Medical Devices, Hospitals, Neurology, Science, Medical Supplies, Clinical Trials, Biotechnology, Health, Health Technology, Health Insurance, Other Science, Research, Radiology, Pharmaceutical, Seniors, Radiation, APS2, Certification, Brain, Alzheimer's disease, Deficit spending, Disease, Memory, AUC, Patient, Ageing, PET, Journal, Apolipoprotein, City, CLIA, Pathology, Medicare, Amyloid, Medical imaging

The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.

Key Points: 
  • The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.
  • The APS2 result was the most robust method among the individual plasma amyloid and tau analytes measured to identify disease.
  • In the published study, the PrecivityAD2 blood test was clinically validated in 583 individuals with cognitive impairment across two independent cohorts.
  • C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD2 test to be available in New York in the near future.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Mental Health, Chemicals, Plastics, Manufacturing, Other Health, Depression, Cannabinoid, Rheumatoid arthritis, Patient, Anxiety, IND, Addiction, Pathology, Therapy, Osteoarthritis, Arthropathy, Steroid, Pharmaceutical industry

The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.

Key Points: 
  • The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.
  • Royalty rates could range from 2.5% up to 10% on future sales, depending on meeting certain sales criteria.
  • Together, through the out-licensing of the two assets and meeting various development and sales milestones, Enveric could potentially receive milestone payments that total up to approximately $82 million.
  • “We look forward to working with our partner, and we are confident in their leadership and capabilities to continue the development of these compounds for both pharmaceutical and non-pharmaceutical applications to advance joint disease treatment options for patients.

OBIO® Celebrates International Women’s Day with Investment in Three Women-Led Companies and a Successful Graduation of First Seed Funding Cohort

Retrieved on: 
Thursday, March 14, 2024
General Health, Health, Other Philanthropy, Philanthropy, Health Technology, Stem Cell Network, Chimney, Government, Woman, Associate, Partnership, International, Phoenix Fire, Knowledge, The Honourable, OCI, Doctor Who, Entrepreneurship, Investment, FACIT, Therapy, Ecosystem, Pathology, Organization, Pharmaceutical industry

The program offers comprehensive training, support and networking opportunities, empowering women with the skills and knowledge required to excel in leadership positions.

Key Points: 
  • The program offers comprehensive training, support and networking opportunities, empowering women with the skills and knowledge required to excel in leadership positions.
  • The OBIO® WiHI has supported more than 325 women in the health science industry through a combination of experiential learning and financial support.
  • The WiHI Seed Program addresses the significant barriers that women-led health science companies face in accessing financing.
  • WiHI Seed cohort companies also made several announcements during the March 8 event, including the successful closing of their first financing rounds for Noa Therapeutics and Tenomix.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

Sunbird Bio to Present Findings From Study Assessing Key Alzheimer’s Disease Biomarker at the Tau2024 Global Conference

Retrieved on: 
Wednesday, March 13, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, General Health, Science, Oncology, Diagnosis, EV, Brain, Conference, Innovation, Disease, Alzheimer's disease, APEX, Protein, DSM-IV codes, Pathology, Therapy, Blood

“Utilizing our APEX diagnostic platform, we are continuing to expand our portfolio of blood-based tests in neurological disorders such as Alzheimer’s disease and Parkinson’s disease.

Key Points: 
  • “Utilizing our APEX diagnostic platform, we are continuing to expand our portfolio of blood-based tests in neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
  • APEX, Sunbird Bio’s lead technology platform, is the first platform that directly detects EV-bound disease-specific proteins that aggregate in the brain.
  • Data to date have shown it is capable of detecting another key Alzheimer’s disease protein, amyloid beta, and other proteins associated with neurological disorders.
  • Following are details about the poster presentation at Tau2024:
    Presenter: Nicholas Ho, Ph.D., Head of Innovation and Scientific Co-Founder, Sunbird Bio

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

The College of American Pathologists Welcomes New CEO

Retrieved on: 
Monday, March 11, 2024
Education, Health, General Health, Research, Science, University, College, Mother, Health equity, COVID-19, Public, Accreditation, History, Artificial intelligence, Policy, CAP, Doctor of Philosophy, Oberlin College, Pennsylvania Medical Society, Medicine, FCPP, Michigan State University, CAE, Sociology, Pathology, Multimedia, State, Management

The College of American Pathologists (CAP), the world’s leading organization of board-certified pathologists, announced today that Michael Fraser, PhD, MS, CAE, FCPP, is joining the CAP as its new Chief Executive Officer (CEO).

Key Points: 
  • The College of American Pathologists (CAP), the world’s leading organization of board-certified pathologists, announced today that Michael Fraser, PhD, MS, CAE, FCPP, is joining the CAP as its new Chief Executive Officer (CEO).
  • "I bring a ‘startup energy’ that lets me see things from a fresh perspective—the opportunities as well as the challenges,” said Fraser.
  • His transparent and empowering leadership style has enabled teams to tackle challenging public health issues, including navigating the COVID-19 pandemic.
  • He has authored numerous peer-reviewed scientific publications and nonfiction books on strategic leadership and public health.

CodaMetrix Announces $40M Series B Financing to Advance Medical Coding Quality and Clinically Enrich Claims Data Through AI

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Data Management, Technology, Artificial Intelligence, Organization, Mass General Brigham, Entrepreneurship, Partner (business rank), Acceleration, Artificial intelligence, GI, Radiology, University, Pathology, Mount Sinai Health System, Mass, Emerge Commerce, Medical device

Transformation Capital led the financing with continued support from existing investors SignalFire, Series A lead, and Frist Cressey Ventures.

Key Points: 
  • Transformation Capital led the financing with continued support from existing investors SignalFire, Series A lead, and Frist Cressey Ventures.
  • Series B financing will be used to further advance CodaMetrix’s AI-powered solutions which improve medical coding quality, produce clinically comprehensive data sets, reduce the overall cost of care, and alleviate administrative burden on providers.
  • “Medical coding is one of the most time-consuming, understaffed and inherently error-prone parts of the health system revenue cycle.
  • “Our game changing AI platform delivers vital automation which not only addresses these pain points but, more significantly, changes claims data from notoriously unreliable to clinically valuable.

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Retrieved on: 
Monday, March 11, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, QC, GPU, Utrecht University, Pharmacy, IRT, Drug discovery, Radboud University Nijmegen, Cell biology, Biomarker, Molecular genetics, Bruker, University, Ultra, University of Michigan, Proteomics, Peptide, Infection, Pulse, Neoplasm, Glycomics, Lunenfeld-Tanenbaum Research Institute, TIMS, Multimedia, Medical director, BRKR, Pathology, Medical device

At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.

Key Points: 
  • At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.
  • The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker.
  • Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling.
  • Our software suite supports the analysis of PASEF data, and we are delighted that Bruker now offers it with timsTOF instruments.